GlassScriptPhysician profile
Anna G Troxler
NPI 1790128726
$2,636.88
in general payments reported to CMS, 2019-2025
38 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $44.38 · 2021: $77.16 · 2022: $543 · 2023: $1,031 · 2024: $415 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,592 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,592.05 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $374.90 | 2021-2024 | Ubrelvy, Qulipta, Lo Loestrin Fe |
| Astellas Pharma US INC | $290.43 | 2023-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $278.05 | 2022-2024 | Slynd |
| Mayne Pharma Commercial LLC | $173.10 | 2022-2025 | |
| Novo Nordisk INC | $170.64 | 2023-2024 | Wegovy, Saxenda |
| Evofem Biosciences, INC. | $150.63 | 2022-2025 | Phexxi, Solosec, Phexx |
| Baxter Healthcare | $104.24 | 2021-2025 | Tisseel, Seprafilm |
| Bayer Healthcare Pharmaceuticals INC. | $99.89 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $84.55 | 2023-2024 | Myfembree |
| Daiichi Sankyo INC. | $83.06 | 2021-2022 | |
| Myovant Sciences INC. | $66.46 | 2022 | |
| Lupin INC. | $66.44 | 2019 | |
| Channel Medsystems, INC. | $52.24 | 2023 | |
| Allergan, INC. | $51.46 | 2019-2022 | |
| Coopersurgical, INC. | $45.75 | 2020-2024 | Paragard T 380a |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $45.41 | 2022-2025 | Nexplanon |
| Pfizer INC. | $44.89 | 2024 | |
| Medtronic, INC. | $44.14 | 2024 | Interstim |
| Ibsa Pharma INC. | $38.95 | 2022 | |
| Amag Pharmaceuticals, INC. | $30.95 | 2019 | |
| Biogen, INC. | $27.78 | 2025 | Zurzuvae |
| Dexcom, INC. | $26.70 | 2025 | Dexcom G6 Transmitter |
| Biom'Up Sa | $25.23 | 2019 | |
| Ethicon US, LLC | $25.12 | 2019 | |
| Medline Industries LP | $25.01 | 2022 | |
| Duchesnay USA Incorporated | $23.03 | 2019 | |
| Phadia US INC. | $19.51 | 2022 | |
| Roche Diagnostics Corporation | $18.02 | 2019 | |
| Therapeuticsmd, INC. | $17.99 | 2019 | |
| Scynexis, INC. | $17.05 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.72 | 2023 | Adthyza |
| Cumberland Pharmaceuticals, INC. | $16.29 | 2024 | Caldolor |
| Boston Scientific Corporation | $15.76 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.68 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.60 | 2022 | |
| Exact Sciences Corporation | $13.42 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $13.08 | 2020 | |
| Hologic Sales and Service, LLC | $12.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Troxler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.